Molecular Biotechnology

, 43:250 | Cite as

Gene Delivery Efficiency in Bone Marrow-derived Dendritic Cells: Comparison of Four Methods and Optimization for Lentivirus Transduction

  • Gong-Bo Li
  • Guang-Xiu Lu


Many gene delivery methods have been used to transduce or transfect bone marrow-derived dendritic cells (BMDCs) for genetic engineered DC vaccine research. The present study, for the first time, evaluated the efficiencies of four methods (lipofection, DNA electroporation, recombinant adeno-associated virus type 2 (rAAV2) transduction, and recombinant lentivirus (rLV) transduction) using EGFP as a report gene in the same BMDC culture system. Our data demonstrate that rLV transduction is the most effective method; both lipofection and DNA electroporation transfect BMDCs at lower efficiencies; rAAV2 can hardly transduce BMDCs. Furthermore, our results, for the first time, demonstrate that rLV transduction efficiency on BMDCs can be improved significantly by co-centrifugation and repeated transduction.


Dendritic cell Lentivirus Gene delivery 



Bone marrow-derived dendritic cell


Granulocyte–macrophage colony-stimulating factor


Recombinant lentivirus


Recombinant adeno-associated virus type 2


Multiplicity of infection


Transduction unit


Antigen presenting cell



This study was supported by The Hi-Tech Research and Development of China, Grant No. 2006AA02A102.


  1. 1.
    Yang, S. X., Vervaert, C. E., Burch, J., Jr., Grichnik, J., Seigler, H. F., & Darrow, T. L. (1999). Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. International Journal of Cancer, 83, 532–540.CrossRefGoogle Scholar
  2. 2.
    Ke, S., Chen, X. H., Li, H., Li, J. F., Gu, Q. L., Zhu, Z. G., et al. (2006). Optimization of electroporation parameters for transfection of plasmid DNA into mature bone marrow derived dendritic cell. Journal of Shanghai Second Medical University, 18, 71–76.Google Scholar
  3. 3.
    Zhang, Y., Chirmule, N., Gao, G. P., & Wilson, J. M. (2000). CD40 ligand dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: Role of immature dendritic cells. Journal of Virology, 74, 8003–8010.CrossRefGoogle Scholar
  4. 4.
    Breckpot, K., Dullaers, M., Bonehill, A., van Meirvenne, S., Heirman, C., de Greef, C., et al. (2003). Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. Journal of Gene Medicine, 5, 654–667.CrossRefGoogle Scholar
  5. 5.
    Rouas, R., Uch, R., Cleuter, Y., Jordier, F., Bagnis, C., Mannoni, P., et al. (2002). Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: Optimized design and procedures for highly efficient transduction compatible with clinical constraints. Cancer Gene Therapy, 9, 715–724.CrossRefGoogle Scholar
  6. 6.
    Lutz, M. B., Kukutsch, N., Ogilvie, A. L. J., Rössner, S., Koch, F., Romani, N., et al. (1999). An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. Journal of Immunological Methods, 223, 77–92.CrossRefGoogle Scholar
  7. 7.
    Auricchio, A., Hildinger, M., O’Connor, E., Gao, G. P., & Wilson, J. M. (2001). Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Human Gene Therapy, 12, 71–76.CrossRefGoogle Scholar
  8. 8.
    Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272, 263–267.CrossRefGoogle Scholar
  9. 9.
    Van Meirvenne, S., Straetman, L., Heirman, C., Dullaers, M., De Greef, C., Van Tendeloo, V., et al. (2002). Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Therapy, 9, 787–797.CrossRefGoogle Scholar
  10. 10.
    Bartlett, J. S., Wilcher, R., & Jude Samulski, R. (2000). Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. Journal of Virology, 74, 2777–2785.CrossRefGoogle Scholar
  11. 11.
    Liang, C. M., Ye, S. L., Zhong, C. P., Zheng, N., Bian, W., Sun, R. X., et al. (2007). More than chemotaxis: A new anti-tumor DC vaccine modified by rAAV2-SLC. Molecular Immunology, 44, 3797–3804.CrossRefGoogle Scholar
  12. 12.
    He, Y. K., Zhang, J. Y., Mi, Z. B., Robbins, P., & Falo, L. D. Jr. (2005). Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. Journal of Immunology, 174, 3808–3817.Google Scholar
  13. 13.
    Firat, H., Zennou, V., Garcia-Pons, F., Ginhoux, F., Madeleine, C., Danos, O., et al. (2002). Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. Journal of Gene Medicine, 4, 38–45.CrossRefGoogle Scholar

Copyright information

© Humana Press 2009

Authors and Affiliations

  1. 1.Institute of Human Reproduction and Stem Cell EngineeringCentral South University, National Engineering and Research Center of Human Stem CellChangshaChina

Personalised recommendations